{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020841","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.408093+00:00","generated_at":"2026-06-02T17:25:26.242807+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market","bullets":["Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).","Net income of $61.0M ($0.36 basic EPS) vs net loss of $61.7M in Q1 2023.","FDA approved label expansions for NEXLETOL/NEXLIZET to add CV risk reduction and use without statin.","Cash balance $226.6M at quarter end, up from $82.2M at Dec 31, 2023.","FY 2024 operating expense guidance maintained at $225M-$245M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020841","json":"https://secwatch.observer/filing/0001628280-24-020841.json","markdown":"https://secwatch.observer/filing/0001628280-24-020841.md","text":"https://secwatch.observer/filing/0001628280-24-020841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/0001628280-24-020841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/espr-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:25:26.242807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6883f13f1974fd8e4cb157625b1ea25fb68ac222","claim":"Esperion Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $137.7 million.","evidence_excerpt":"Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/0001628280-24-020841-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$137.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}